scramble control hairpin sequence (Addgene inc)
Addgene inc is a verified supplier 
96
Structured Review
Addgene inc
scramble control hairpin sequence
Scramble Control Hairpin Sequence, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1089 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/scramble+control+hairpin+sequence/scramble+shRNA+(Plasmid+%231864)/pmc07706707-682-47-59
Average 96 stars, based on 1089 article reviews
Scramble Control Hairpin Sequence, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1089 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/scramble+control+hairpin+sequence/scramble+shRNA+(Plasmid+%231864)/pmc07706707-682-47-59
Average 96 stars, based on 1089 article reviews
scramble control hairpin sequence - by Bioz Stars,
2026-09
96/100 stars
Images
Related Articles
shRNA:Article Title: Replication stress conferred by POT1 dysfunction promotes telomere relocalization to the nuclear pore Article Snippet: The shRNAs against TERF2 , namely TRF2 sh-F (Open Biosystems TRCN0000004811) and TRF2 sh-G (Open Biosystems TRCN0000018358), were created in the Salk Institute Gene Transfer, Targeting, and Therapeutics Core or the CMRI Vector and Genome Engineering Facility. .. The shRNAs used were as follows: shRNA_NUP58-A (TRCN0000280396): CCGGGCTTCAGTTTAGGATTCAATACTCGAGTATTGAATCCTAAACTGAAGCTTTTTG; shRNA_ NUP58-B (TRCN0000013517): CCGGGCGGCACAACTTCAGTCTATTCTCGAGAATAGACTGAAGTTGTGCCGCTTTTTG; shRNA_NUP62-A (TRCN0000232576): CCGGGCAACCTCACTAATGCCATATCTCGAGATATGGCATTAGTGAGGTTGCTTTTTG; shRNA_NUP62-B (TRCN0000232579): CCGGGCTTTCATTTGAGTATCTTTGCTCGAGCAAAGATACTCAAATGAAAGCTTTTTG; shRNA_POLD3 (TRCN0000233260): CCGGGATAGTGAAGAGGAGCTTAACCTCGAGGTTAAGCTCCTCTTCACTATCTTTTTG; shRNA_SMC2 (TRCN0000291367): CCGGCCAGATTTACTCAATGTCAAACTCGAGTTTGACATTGAGTAAATCTGGTTTTTG; shRNA_TPR (TRCN0000060066): CCGGGCGATCTGAAACAGAAACCAACTCGAGTTGGTTTCTGTTTCAGATCGCTTTTTG; shRNA_NUP153 (TRCN0000290594): CCGGCCCAGTTTCTTTAACTCCATTCTCGAGAATGGAGTTAAAGAAACTGGGTTTTTG; shRNA_ HUS1 (TRCN0000439497): CCGGGCGCACAGTCAGTCTTG CATTCTCGAGAATGCAAGACTGACTGTGCGCTTTTTG; shRNA_TRF2 (TRCN0000004811, sh-F): CCGGGCGCATGACAATAAGCAGATTCTCGAGAATCTGCTTATTGTCATGCGCTTTTTG; and shRNA TRF2 (TRCN0000018358, sh-G): CCGGGACAGAAGCAGTGGTCGAATCCTCGAGGATTCGACCACTGCTTCTGTCTTTTTG; and Control:Article Title: Replication stress conferred by POT1 dysfunction promotes telomere relocalization to the nuclear pore Article Snippet: The shRNAs against TERF2 , namely TRF2 sh-F (Open Biosystems TRCN0000004811) and TRF2 sh-G (Open Biosystems TRCN0000018358), were created in the Salk Institute Gene Transfer, Targeting, and Therapeutics Core or the CMRI Vector and Genome Engineering Facility. .. The shRNAs used were as follows: shRNA_NUP58-A (TRCN0000280396): CCGGGCTTCAGTTTAGGATTCAATACTCGAGTATTGAATCCTAAACTGAAGCTTTTTG; shRNA_ NUP58-B (TRCN0000013517): CCGGGCGGCACAACTTCAGTCTATTCTCGAGAATAGACTGAAGTTGTGCCGCTTTTTG; shRNA_NUP62-A (TRCN0000232576): CCGGGCAACCTCACTAATGCCATATCTCGAGATATGGCATTAGTGAGGTTGCTTTTTG; shRNA_NUP62-B (TRCN0000232579): CCGGGCTTTCATTTGAGTATCTTTGCTCGAGCAAAGATACTCAAATGAAAGCTTTTTG; shRNA_POLD3 (TRCN0000233260): CCGGGATAGTGAAGAGGAGCTTAACCTCGAGGTTAAGCTCCTCTTCACTATCTTTTTG; shRNA_SMC2 (TRCN0000291367): CCGGCCAGATTTACTCAATGTCAAACTCGAGTTTGACATTGAGTAAATCTGGTTTTTG; shRNA_TPR (TRCN0000060066): CCGGGCGATCTGAAACAGAAACCAACTCGAGTTGGTTTCTGTTTCAGATCGCTTTTTG; shRNA_NUP153 (TRCN0000290594): CCGGCCCAGTTTCTTTAACTCCATTCTCGAGAATGGAGTTAAAGAAACTGGGTTTTTG; shRNA_ HUS1 (TRCN0000439497): CCGGGCGCACAGTCAGTCTTG CATTCTCGAGAATGCAAGACTGACTGTGCGCTTTTTG; shRNA_TRF2 (TRCN0000004811, sh-F): CCGGGCGCATGACAATAAGCAGATTCTCGAGAATCTGCTTATTGTCATGCGCTTTTTG; and shRNA TRF2 (TRCN0000018358, sh-G): CCGGGACAGAAGCAGTGGTCGAATCCTCGAGGATTCGACCACTGCTTCTGTCTTTTTG; and Sequencing:Article Title: Replication stress conferred by POT1 dysfunction promotes telomere relocalization to the nuclear pore Article Snippet: The shRNAs against TERF2 , namely TRF2 sh-F (Open Biosystems TRCN0000004811) and TRF2 sh-G (Open Biosystems TRCN0000018358), were created in the Salk Institute Gene Transfer, Targeting, and Therapeutics Core or the CMRI Vector and Genome Engineering Facility. .. The shRNAs used were as follows: shRNA_NUP58-A (TRCN0000280396): CCGGGCTTCAGTTTAGGATTCAATACTCGAGTATTGAATCCTAAACTGAAGCTTTTTG; shRNA_ NUP58-B (TRCN0000013517): CCGGGCGGCACAACTTCAGTCTATTCTCGAGAATAGACTGAAGTTGTGCCGCTTTTTG; shRNA_NUP62-A (TRCN0000232576): CCGGGCAACCTCACTAATGCCATATCTCGAGATATGGCATTAGTGAGGTTGCTTTTTG; shRNA_NUP62-B (TRCN0000232579): CCGGGCTTTCATTTGAGTATCTTTGCTCGAGCAAAGATACTCAAATGAAAGCTTTTTG; shRNA_POLD3 (TRCN0000233260): CCGGGATAGTGAAGAGGAGCTTAACCTCGAGGTTAAGCTCCTCTTCACTATCTTTTTG; shRNA_SMC2 (TRCN0000291367): CCGGCCAGATTTACTCAATGTCAAACTCGAGTTTGACATTGAGTAAATCTGGTTTTTG; shRNA_TPR (TRCN0000060066): CCGGGCGATCTGAAACAGAAACCAACTCGAGTTGGTTTCTGTTTCAGATCGCTTTTTG; shRNA_NUP153 (TRCN0000290594): CCGGCCCAGTTTCTTTAACTCCATTCTCGAGAATGGAGTTAAAGAAACTGGGTTTTTG; shRNA_ HUS1 (TRCN0000439497): CCGGGCGCACAGTCAGTCTTG CATTCTCGAGAATGCAAGACTGACTGTGCGCTTTTTG; shRNA_TRF2 (TRCN0000004811, sh-F): CCGGGCGCATGACAATAAGCAGATTCTCGAGAATCTGCTTATTGTCATGCGCTTTTTG; and shRNA TRF2 (TRCN0000018358, sh-G): CCGGGACAGAAGCAGTGGTCGAATCCTCGAGGATTCGACCACTGCTTCTGTCTTTTTG; and Plasmid Preparation:Article Title: Replication stress conferred by POT1 dysfunction promotes telomere relocalization to the nuclear pore Article Snippet: The shRNAs against TERF2 , namely TRF2 sh-F (Open Biosystems TRCN0000004811) and TRF2 sh-G (Open Biosystems TRCN0000018358), were created in the Salk Institute Gene Transfer, Targeting, and Therapeutics Core or the CMRI Vector and Genome Engineering Facility. .. The shRNAs used were as follows: shRNA_NUP58-A (TRCN0000280396): CCGGGCTTCAGTTTAGGATTCAATACTCGAGTATTGAATCCTAAACTGAAGCTTTTTG; shRNA_ NUP58-B (TRCN0000013517): CCGGGCGGCACAACTTCAGTCTATTCTCGAGAATAGACTGAAGTTGTGCCGCTTTTTG; shRNA_NUP62-A (TRCN0000232576): CCGGGCAACCTCACTAATGCCATATCTCGAGATATGGCATTAGTGAGGTTGCTTTTTG; shRNA_NUP62-B (TRCN0000232579): CCGGGCTTTCATTTGAGTATCTTTGCTCGAGCAAAGATACTCAAATGAAAGCTTTTTG; shRNA_POLD3 (TRCN0000233260): CCGGGATAGTGAAGAGGAGCTTAACCTCGAGGTTAAGCTCCTCTTCACTATCTTTTTG; shRNA_SMC2 (TRCN0000291367): CCGGCCAGATTTACTCAATGTCAAACTCGAGTTTGACATTGAGTAAATCTGGTTTTTG; shRNA_TPR (TRCN0000060066): CCGGGCGATCTGAAACAGAAACCAACTCGAGTTGGTTTCTGTTTCAGATCGCTTTTTG; shRNA_NUP153 (TRCN0000290594): CCGGCCCAGTTTCTTTAACTCCATTCTCGAGAATGGAGTTAAAGAAACTGGGTTTTTG; shRNA_ HUS1 (TRCN0000439497): CCGGGCGCACAGTCAGTCTTG CATTCTCGAGAATGCAAGACTGACTGTGCGCTTTTTG; shRNA_TRF2 (TRCN0000004811, sh-F): CCGGGCGCATGACAATAAGCAGATTCTCGAGAATCTGCTTATTGTCATGCGCTTTTTG; and shRNA TRF2 (TRCN0000018358, sh-G): CCGGGACAGAAGCAGTGGTCGAATCCTCGAGGATTCGACCACTGCTTCTGTCTTTTTG; and |